Cumberland Pharmaceuticals (CPIX) Competitors

$4.92 +0.07 (+1.44%)

Closing price 04:00 PM Eastern

Extended Trading

$4.90 -0.01 (-0.30%)

As of 04:10 PM Eastern

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? MarketBeat compares Cumberland Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cumberland Pharmaceuticals include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Eli Lilly and Company (NYSE:LLY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Cumberland Pharmaceuticals has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Eli Lilly and Company has a consensus target price of $1,218.33, suggesting a potential upside of 21.01%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts plainly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	2.87

In the previous week, Eli Lilly and Company had 154 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 157 mentions for Eli Lilly and Company and 3 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.93 beat Cumberland Pharmaceuticals' score of 0.29 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	87 Very Positive mention(s)	30 Positive mention(s)	26 Neutral mention(s)	7 Negative mention(s)	4 Very Negative mention(s)	Positive

Eli Lilly and Company has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.66	-$2.84M	-$0.49	N/A
Eli Lilly and Company	$65.18B	14.55	$20.64B	$28.15	35.77

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Eli Lilly and Company has a net margin of 34.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Eli Lilly and Company's return on equity of 105.77% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Eli Lilly and Company	34.98%	105.77%	23.76%

Summary

Eli Lilly and Company beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Cumberland Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Johnson & Johnson has a net margin of 21.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Johnson & Johnson's return on equity of 32.60% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Johnson & Johnson	21.83%	32.60%	13.29%

Johnson & Johnson has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	1.66	-$2.84M	-$0.49	N/A
Johnson & Johnson	$94.19B	5.89	$26.80B	$8.65	26.66

In the previous week, Johnson & Johnson had 76 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 79 mentions for Johnson & Johnson and 3 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 1.27 beat Cumberland Pharmaceuticals' score of 0.29 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	58 Very Positive mention(s)	8 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Johnson & Johnson has a consensus target price of $253.04, suggesting a potential upside of 9.73%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Johnson & Johnson beats Cumberland Pharmaceuticals on 15 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to AbbVie?

AbbVie (NYSE:ABBV) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

AbbVie has a net margin of 5.79% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	5.79%	-576.45%	13.39%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

AbbVie has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$62.82B	5.93	$4.23B	$2.03	103.92
Cumberland Pharmaceuticals	$44.52M	1.66	-$2.84M	-$0.49	N/A

AbbVie has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

In the previous week, AbbVie had 52 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 55 mentions for AbbVie and 3 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 1.20 beat Cumberland Pharmaceuticals' score of 0.29 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	35 Very Positive mention(s)	9 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.2% of AbbVie shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

AbbVie presently has a consensus target price of $253.10, suggesting a potential upside of 19.98%. Given AbbVie's stronger consensus rating and higher possible upside, equities research analysts clearly believe AbbVie is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

AbbVie beats Cumberland Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Merck & Co., Inc. currently has a consensus price target of $128.18, indicating a potential upside of 13.23%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.68
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Merck & Co., Inc. has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Merck & Co., Inc. has a net margin of 13.59% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Merck & Co., Inc.'s return on equity of 27.55% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	13.59%	27.55%	10.73%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Merck & Co., Inc. has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.77B	4.25	$18.25B	$3.55	31.89
Cumberland Pharmaceuticals	$44.52M	1.66	-$2.84M	-$0.49	N/A

In the previous week, Merck & Co., Inc. had 42 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 45 mentions for Merck & Co., Inc. and 3 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.06 beat Cumberland Pharmaceuticals' score of 0.29 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	33 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by company insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Merck & Co., Inc. beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Pfizer?

Pfizer (NYSE:PFE) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Pfizer has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.34	$7.77B	$1.31	19.65
Cumberland Pharmaceuticals	$44.52M	1.66	-$2.84M	-$0.49	N/A

Pfizer has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Pfizer's return on equity of 19.44% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	11.83%	19.44%	8.41%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

Pfizer presently has a consensus price target of $28.84, indicating a potential upside of 12.05%. Given Pfizer's stronger consensus rating and higher possible upside, research analysts clearly believe Pfizer is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	3 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.23
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pfizer had 71 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 74 mentions for Pfizer and 3 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.82 beat Cumberland Pharmaceuticals' score of 0.29 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	40 Very Positive mention(s)	13 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Pfizer beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$73.70M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-10.04	19.11	20.87	25.58
Price / Sales	1.66	278.37	521.63	63.56
Price / Cash	12.35	56.53	42.94	55.34
Price / Book	3.46	4.35	9.86	6.70
Net Income	-$2.84M	$72.19M	$3.55B	$333.77M
7 Day Performance	15.11%	-0.60%	-0.32%	0.45%
1 Month Performance	54.72%	0.25%	1.34%	4.06%
1 Year Performance	-0.81%	46.24%	41.03%	36.21%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.2248 of 5 stars	$4.92 +1.4%	N/A	-12.8%	$73.70M	$44.52M	N/A	80	Short Interest Increase
LLY Eli Lilly and Company	4.9065 of 5 stars	$989.02 +2.2%	$1,217.59 +23.1%	+36.1%	$911.54B	$65.18B	35.13	50,000	Trending News Analyst Revision
JNJ Johnson & Johnson	4.6189 of 5 stars	$225.59 +0.6%	$252.48 +11.9%	+55.0%	$539.70B	$94.19B	26.08	138,200	Trending News Analyst Upgrade
ABBV AbbVie	4.9333 of 5 stars	$206.12 -1.0%	$252.90 +22.7%	+10.9%	$368.06B	$61.16B	101.54	57,000	Positive News Analyst Forecast Analyst Revision
MRK Merck & Co., Inc.	4.7549 of 5 stars	$113.21 +0.1%	$128.18 +13.2%	+48.2%	$279.37B	$65.01B	31.89	75,000	Trending News Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Which has more volatility & risk, CPIX or LLY?

Do analysts prefer CPIX or LLY?

Does the media refer more to CPIX or LLY?

Which has better valuation and earnings, CPIX or LLY?

Do institutionals & insiders have more ownership in CPIX or LLY?

Is CPIX or LLY more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Which has more volatility and risk, CPIX or JNJ?

Is CPIX or JNJ more profitable?

Which has better valuation and earnings, CPIX or JNJ?

Does the media prefer CPIX or JNJ?

Do analysts rate CPIX or JNJ?

Do institutionals and insiders have more ownership in CPIX or JNJ?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Is ABBV or CPIX more profitable?

Which has preferable earnings and valuation, ABBV or CPIX?

Which has more risk and volatility, ABBV or CPIX?

Does the media refer more to ABBV or CPIX?

Do institutionals & insiders hold more shares of ABBV or CPIX?

Do analysts prefer ABBV or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Do analysts recommend MRK or CPIX?

Which has more volatility & risk, MRK or CPIX?

Is MRK or CPIX more profitable?

Which has stronger valuation & earnings, MRK or CPIX?

Does the media prefer MRK or CPIX?

Do institutionals and insiders believe in MRK or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Which has higher valuation and earnings, PFE or CPIX?

Which has more risk & volatility, PFE or CPIX?

Is PFE or CPIX more profitable?

Do analysts recommend PFE or CPIX?

Does the media favor PFE or CPIX?

Do institutionals and insiders believe in PFE or CPIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools